Illumina reported financial results for second quarter fiscal 2026
Revenue rose 9.5% to $1.16 billion, and the company raised its full-year guidance.
See the latest news and media coverage for Illumina. We track all announcements, press releases, and industry mentions in real time, all in one place.
Genomic sequencing and array technology company
illumina.comLast updated
In short: Illumina reported strong Q2 2026 financial results with $1.16 billion in revenue and expanded its AI-driven drug discovery partnerships.
Revenue rose 9.5% to $1.16 billion, and the company raised its full-year guidance.
The alliance includes Formation Bio and other AI-driven drug developers to advance precision medicines using genomic perturbation data.
The new leaders bring experience in life sciences and diagnostics, effective July 20 and August 3, 2026.
The results will be released after market close on July 30, 2026, followed by a conference call with analysts.
Illumina (ILMN) stock sees $57M insider sale by Director Keith Meister ahead of September 21 S&P 500 reinstatement. Shares up 66% YTD trading near $218.
Molson Coors Beverage, Builders FirstSource and Trade Desk will be getting the boot from the...
Illumina (ILMN) Analyst Rating Upgrade - A Comprehensive Analysis On October 12, 2023, UBS upgraded Illumina (ILMN) to a Buy rating with a new price...
On September 03, 2026, Illumina Inc (ILMN) shares rose by 3.9%, bringing the current price to...
Track Illumina and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Illumina and other trending companies.